UAMS, MEMS to Participate in Study for Early Treatment of Trauma Patients
| LITTLE ROCK — Researchers at the University of Arkansas for Medical Sciences (UAMS) are partnering with the University of Pittsburgh to study whether calcium, vasopressin, or both, will help severely injured patients survive life-threatening blood loss early in treatment.
The CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) trial will include approximately 1,050 people, ages 18 to 90. Patients who have traumatic injuries with loss of blood may be enrolled by participating emergency medical personnel during their transportation to UAMS or after arrival.
CAVALIER is an Exception from Informed Consent (EFIC) trial, meaning that the trial requires performing a potentially life-saving treatment in people who are too injured to give permission. This study will look at treatment for patients who have a traumatic injury and have lost a lot of blood. These patients are too injured to give permission before receiving the study drug. Permission for continued participation will be obtained from patients once they are able, or as soon as possible from their family members.
Standard treatments for injured patients who are bleeding include the transfusion of different types of blood products, the use of medications to help the blood clot better, and surgery to stop the bleeding. Even with these treatments, up to 30% of patients die with a serious traumatic injury.
“We are committed at UAMS to helping improve survival rates of these severely injured patients,” said Joseph Margolick, M.D., a trauma surgeon and the UAMS principal investigator on the study. “We think early treatment with calcium and vasopressin in trauma patients may improve outcomes.”
For more information about CAVALIER, including how people can optout from being enrolled in the study, or to complete an anonymous survey on your thoughts about this EFIC study, please go to litesnetwork.org/CAVALIER/.
This research is supported by Department of Defense (DOD) contract W81XWH-16-D-0024 W81XWH-22-F-0118. Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the Department of the Army, Department of Defense or the U.S. Government.
The study is also supported by the UAMS Translational Research Institute, which is funded by the National Center for Advancing Translational Sciences of the National Institutes of Health, Clinical and Translational Science Award number UM1 TR004909.
UAMS is the state’s only health sciences university, with colleges of Medicine, Nursing, Pharmacy, Health Professions and Public Health; a graduate school; a hospital; a main campus in Little Rock; a Northwest Arkansas regional campus in Fayetteville; a statewide network of regional campuses; and eight institutes: the Winthrop P. Rockefeller Cancer Institute, Jackson T. Stephens Spine & Neurosciences Institute, Harvey & Bernice Jones Eye Institute, Psychiatric Research Institute, Donald W. Reynolds Institute on Aging, Translational Research Institute, Institute for Digital Health & Innovation and the Institute for Community Health Innovation. UAMS includes UAMS Health, a statewide health system that encompasses all of UAMS’ clinical enterprise. UAMS is the only adult Level 1 trauma center in the state. UAMS has 3,485 students, 915 medical residents and fellows, and seven dental residents. It is the state’s largest public employer with more than 11,000 employees, including 1,200 physicians who provide care to patients at UAMS, its regional campuses, Arkansas Children’s, the VA Medical Center and Baptist Health. Visit www.uams.edu or uamshealth.com. Find us on Facebook, X (formerly Twitter), YouTube or Instagram.###